SurvodutideBI 456906
A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver.
Not more receptors, but a different pair — GLP-1 and glucagon — chosen so the second note is aimed at the liver. Which signals you combine turns out to matter as much as how many.
Identity
- Class
- Glucagon/GLP-1 dual receptor agonist (acylated peptide)
- Source
- Synthetic; engineered dual agonist (Boehringer Ingelheim / Zealand Pharma)
- Receptor
- Glucagon receptor (GCGR) + GLP-1 receptor
Key properties
Evidence floorClinicalREF1CLIN1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Survodutide activates two receptors from one acylated, once-weekly peptide — but a different pair than tirzepatide's. It keeps the GLP-1 arm for appetite and glucose-dependent insulin, and adds the glucagon receptor rather than GIP. Glucagon-receptor agonism raises energy expenditure and drives hepatic fat oxidation, which points the molecule at the liver as much as the scale. The GLP-1 arm is what keeps glucagon's tendency to raise blood glucose in check.
In depth
Survodutide is the co-agonist that made a different bet. Tirzepatide reads two receptors, GLP-1 and GIP; retatrutide reads three, adding glucagon. Survodutide drops GIP entirely and pairs GLP-1 with glucagon alone — two notes, but not the two everyone else plays. The whole molecule is a wager that the glucagon receptor, not the second incretin, is the arm worth adding to GLP-1.
The reason is the liver. Glucagon on its own is a diabetes drug's enemy — it raises blood glucose — but it also turns up the body's resting burn and, crucially, pushes the liver to oxidize its own stored fat. Balance it against a GLP-1 arm strong enough to keep glucose in line and you get a molecule pointed at hepatic fat as much as body weight. That is why survodutide's most striking result is not its ~19% weight loss but its MASH data: in phase 2 the great majority of participants cleared steatohepatitis without their fibrosis worsening, a class-leading liver signal that earned an FDA Breakthrough Therapy tag. The cost of the glucagon arm is the thing to respect — it can nudge glucose and heart rate the wrong way, which is exactly why the dose is titrated slowly rather than started where it lands.
For the near-future marketplace the honest read is the same one this site keeps returning to: cataloged is not the same as proven. Survodutide is arriving on the grey market ahead of its phase 3 verdict, so a buyer is reaching a molecule whose obesity and MASH promise rests on phase 2 and whose long-horizon safety simply has not been measured — on top of the usual unknowns of an unapproved, self-sourced peptide (identity, purity, and dose). Bullish on the biology, sceptical on the page. What is reachable this month is real information; it is not the same information as what works.
Reference notes
- A glucagon/GLP-1 dual agonist — the same two-receptor idea as tirzepatide, but with glucagon in place of GIP, so the second arm spends energy and mobilizes liver fat rather than amplifying insulin.
- Developed by Boehringer Ingelheim with Zealand Pharma as a once-weekly subcutaneous injection; investigational and not approved for any use.
- In a phase 2 obesity trial the highest dose reduced body weight by roughly 19% at 46 weeks, with the curve still falling at the end (Le Roux et al., Lancet 2024).
- Its standout signal is hepatic: in a phase 2 MASH trial up to ~83% of participants had MASH improvement without worsening fibrosis versus ~18% on placebo (Sanyal et al., NEJM 2024) — the result behind its FDA Breakthrough Therapy designation in MASH.
- The glucagon arm is double-edged: glucagon alone raises glucose and can lift heart rate, so the design leans on the GLP-1 arm and slow dose titration to hold glycemia — a reason the class is escalated gradually, never started at target dose.
- Phase 3 is the deciding evidence: the SYNCHRONIZE obesity program and a phase 3 MASH trial are underway. Nothing here is settled, and it is reaching research-chemical catalogs well ahead of that readout — availability running far in front of the evidence, with no long-term human safety data behind it.
Common questions
- What is Survodutide (BI 456906)?
- A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. Structurally it is Glucagon/GLP-1 dual receptor agonist (acylated peptide).
- How does BI 456906 work?
- Survodutide activates two receptors from one acylated, once-weekly peptide — but a different pair than tirzepatide's. It keeps the GLP-1 arm for appetite and glucose-dependent insulin, and adds the glucagon receptor rather than GIP. Glucagon-receptor agonism raises energy expenditure and drives hepatic fat oxidation, which points the molecule at the liver as much as the scale. The GLP-1 arm is what keeps glucagon's tendency to raise blood glucose in check.
- How strong is the evidence for BI 456906?
- PeptideHormone grades BI 456906 at the "Investigational" evidence tier — it is under active human investigation — promising, but not yet settled. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of BI 456906?
- The reported circulating half-life of BI 456906 is engineered for once-weekly dosing.